Financing ·
On September 3, 2026, Senti Biosciences Holdings completed the issuance of $2.0 million in Senior Secured Convertible…
SNTISenti Biosciences Holdings, Inc.
On September 3, 2026, Senti Biosciences Holdings completed the issuance of $2.0 million in Senior Secured Convertible Notes to NSG BioInnovation Fund under a Securities Purchase Agreement dated April 27, 2026. The company also entered into an equity commitment letter with an affiliate of Celadon Partners, LLC, agreeing to sell $2.5 million of common stock at the Nasdaq Minimum Price around the time of a merger closing. These transactions are part of broader Subject Transactions involving a potential merger and contingent value rights that may pay up to $60.0 million based on regulatory and sales milestones for product candidate SENTI-202. A preliminary proxy statement was filed on July 21, 2026, with definitive materials expected soon. Senti Biosciences Holdings operates in the biotechnology industry, developing immunotherapies.